Delving into the Latest Updates on Affiliated Hospital of Xuzhou Medical University with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Autologous CAR-T

CAR-T

Oncolytic virus

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	18
Hemic and Lymphatic Diseases	16
Immune System Diseases	12
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Autologous CAR-T	10
CAR-T	5
CAR-NK	2
Oncolytic virus	2
Small molecule drug	1

Top 5 Target	Count

CD19(B-lymphocyte antigen CD19)	3
CD79B(B-cell antigen receptor complex-associated protein beta chain)	1
CD33 x CLL-1	1
CLL-1(C-Type lectin domain family 12 member A)	1
CD38(Lymphocyte differentiation antigen CD38)	1

The integration of immunotherapy and standard chemotherapy holds great promise for enhanced anticancer effects. In this study, we prepared a pH- and glutathione (GSH)-sensitive manganese-doped mesoporous silicon (MMSNs) based drug delivery system by integrating paclitaxel (PTX) and anti-programmed cell death-ligand 1 antibody (aPD-L1), and encapsulating with polydopamine (PDA) for chemoimmunosynergic treatment of ovarian cancer cells. The nanosystem was degraded in response to the tumor weakly acidic and reductive microenvironment. The Mn²⁺ produced by degradation can be used as a contrast agent for magnetic resonance (MR) imaging to provide visual exposure to tumor tissue. The released PTX can not only kill tumor cells directly, but also induce immunogenic death (ICD) of tumor cells, which can play a synergistic therapeutic effect with aPD-L1. Therefore, our study is expected to provide a promising strategy for improving the efficacy of cancer immunotherapy and the detection rate of cancer.

24 Aug 2024·British Journal of Cancer

Correction: DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer

Author: Yin, Hang ; Jiang, Tao ; Chu, Sufang ; Bai, Jin ; Song, Jun ; Shi, Meilin ; Shi, Peicong ; Hou, Pingfu

02 Aug 2024·Oncologie

Clinical applications and perspectives of immune checkpoint inhibitors in oral squamous cell carcinoma

Author: Ru, Liuyu ; Zheng, Jiwei

AbstractImmune checkpoint inhibitors (ICIs) promote antitumour immune responses by blocking inhibitory signals expressed by T cells and have significant clinical benefits in the treatment of oral squamous cell carcinoma (OSCC). With the advancement of immunotherapy, an increasing number of ICIs have been developed or are in clinical trial stages. However, drug resistance and immune-related adverse events (irAEs) associated with ICIs have limited the clinical application of immunotherapy in OSCC, and the optimal drug regimen for ICIs and the optimal duration of ICIs administration also deserves to be further discussed. New therapeutic regimens and drug delivery technologies are key to promoting the further development of ICIs. This article elucidates the mechanism of ICIs’ action and presents a review of their clinical applications and current development status in OSCC. Additionally, it summarizes the current challenges and outlines future research directions for ICIs therapy, with the aim of offering fresh insights to researchers.

100 Deals associated with Affiliated Hospital of Xuzhou Medical University

Login to view more data

100 Translational Medicine associated with Affiliated Hospital of Xuzhou Medical University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

15

Phase 1 Clinical

Phase 2 Clinical

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Anti-LILRB4 CAR-T (The Affiliated Hospital of Xuzhou Medical University) ( LILRB4 )	Acute Myeloid Leukemia More	Phase 2 Clinical
CD19/CD20/CD22 CAR-T therapy ( CD19 x CD20 x CD22 )	B-Cell Leukemia More	Phase 2 Clinical
Anti-CD1a CAR-T cells(The Affiliated Hospital of Xuzhou Medical University) ( CD1A )	T-cell Acute Lymphoblastic Leukemia/Lymphoma More	Phase 2
Anti-CD56 CAR T(The Affiliated Hospital of Xuzhou Medical University) ( CD56 )	Extranodal NK-T-Cell Lymphoma More	Phase 2
Anti-LY9 CAR-T (The Affiliated Hospital of Xuzhou Medical University) ( LY9 )	Hematologic Neoplasms More	Phase 1